Skip to main content
. Author manuscript; available in PMC: 2012 May 3.
Published in final edited form as: N Engl J Med. 2011 Nov 3;365(18):1663–1672. doi: 10.1056/NEJMoa1105185

Table 3.

Adverse Events.

Adverse Event Placebo (N = 78) Ivacaftor (N = 83)
no. of subjects (%)
Any adverse event 78 (100) 82 (99)

Serious adverse event* 33 (42) 20 (24)

 Pulmonary exacerbation 26 (33) 11 (13)

 Hemoptysis 4 (5) 1 (1)

 Hypoglycemia 0 2 (2)

Adverse event leading to study-drug interruption 5 (6) 11 (13)

Adverse event leading to study-drug discontinuation 4 (5) 1 (1)
*

Included are serious adverse events that occurred in more than one subject per group.